Denali Therapeutics Inc. (MUN:4DN)
Germany · Delayed Price · Currency is EUR | Market Cap | 2.68B +27.7% |
| Revenue (ttm) | n/a |
| Net Income | -440.60M |
| EPS | -2.50 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 102 |
| Open | 17.31 |
| Previous Close | 17.01 |
| Day's Range | 17.31 - 17.47 |
| 52-Week Range | 10.92 - 19.54 |
| Beta | n/a |
| RSI | 53.55 |
| Earnings Date | May 13, 2026 |
About Denali Therapeutics
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzym... [Read more]
News
Denali Therapeutics Transcript: Bank of America Global Healthcare Conference 2026
AVLAYAH’s launch for Hunter syndrome is progressing well, with strong early engagement and a clear path to expand the label to adults pending COMPASS study results. The pipeline includes promising programs for Sanfilippo, Pompe, Parkinson’s, and frontotemporal dementia, leveraging a robust platform and global partnerships.
Denali Therapeutics price target lowered to $23 from $25 at Wedbush
Wedbush analyst Laura Chico lowered the firm’s price target on Denali Therapeutics (DNLI) to $23 from $25 and keeps an Outperform rating on the shares. The firm notes the Avlayah…
Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
SOUTH SAN FRANCISCO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the first quarter ended March 31, 2026, and provided business...
Denali Therapeutics price target raised to $34 from $32 at Baird
Baird raised the firm’s price target on Denali Therapeutics (DNLI) to $34 from $32 and keeps an Outperform rating on the shares. The firm updated its model following the return…
Denali Therapeutics price target raised to $39 from $38 at BTIG
BTIG raised the firm’s price target on Denali Therapeutics (DNLI) to $39 from $38 and keeps a Buy rating on the shares as the company regains full rights to investigational…
Denali Therapeutics regains full rights to DNL593
Denali Therapeutics (DNLI) announced that it has received notification from Takeda (TAK) of its decision to terminate the collaboration agreement between the two companies to co-develop and co-commerc...
Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)
SOUTH SAN FRANCISCO, Calif., April 03, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that it has received notification from Takeda of its decision to terminate the c...
Denali Therapeutics price target raised to $35 from $26 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Denali Therapeutics (DNLI) to $35 from $26 and keeps a Buy rating on the shares. The firm says the approval of Avlayah…
Denali Therapeutics price target raised to $42 from $32 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Denali Therapeutics (DNLI) to $42 from $32 and keeps a Buy rating on the shares after the FDA granted accelerated approval for…
Denali Therapeutics price target raised to $42 from $40 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Denali Therapeutics (DNLI) to $42 from $40 and keeps an Overweight rating on the shares after the company received FDA accelerated approval…
Denali Therapeutics price target raised to $31 from $29 at BofA
BofA raised the firm’s price target on Denali Therapeutics (DNLI) to $31 from $29 and keeps a Buy rating on the shares after the company announced the accelerated approval of…
Denali Therapeutics price target raised to $41 from $34 at Stifel
Stifel analyst Paul Matteis raised the firm’s price target on Denali Therapeutics (DNLI) to $41 from $34 and keeps a Buy rating on the shares following Avlayah’s approval for the…
Denali Therapeutics price target raised to $32 from $29 at Baird
Baird raised the firm’s price target on Denali Therapeutics (DNLI) to $32 from $29 and keeps an Outperform rating on the shares. The firm updated its model as the Avlayah…
Denali Therapeutics Transcript: Study update
AVLAYAH received accelerated FDA approval as the first enzyme replacement therapy to cross the blood-brain barrier for Hunter syndrome, showing robust biomarker normalization and clinical improvements in both CNS and peripheral disease. The launch targets 75% of the U.S. treated population, with global expansion planned and a strong foundation for future pipeline growth.
Denali Therapeutics granted FDA approval of AVLAYAH for treatment of MPS II
Denali Therapeutics (DNLI) announced the U.S. FDA has granted accelerated approval for AVLAYAH, the first FDA-approved biologic specifically designed to cross the blood-brain barrier and reach the who...
Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)
SOUTH SAN FRANCISCO, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval for...
Denali Therapeutics Transcript: Stifel 2026 Virtual CNS Forum
2026 is set as a transformative year with the expected approval and launch of tividenofusp alfa for Hunter syndrome, while key pipeline programs in Sanfilippo, Pompe, and Alzheimer's are advancing toward major data readouts and filings by 2027. The company is leveraging its transferrin receptor platform to expand its portfolio and maintain a competitive edge through engineering innovation.
Denali Therapeutics Transcript: Leerink Global Healthcare Conference 2026
A pivotal FDA decision for tividenofusp alfa in Hunter syndrome is imminent, with strong biomarker and clinical data supporting approval. Commercial and pipeline strategies are robust, leveraging a differentiated brain delivery platform and recent financing to expand into multiple rare and neurodegenerative diseases.
FDA reversals leave investors worrying about the fates of other experimental drugs
The FDA in the past year has denied or discouraged applications of at least eight new drugs, according to RTW Investments. The agency initially refused to review Moderna's flu shot before reversing co...
Denali Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
2026 is set to be transformative, with a major regulatory milestone for Hunter syndrome, key data readouts in Parkinson’s and FTD, and commercial launch preparations well underway. Robust clinical data, global expansion plans, and a strong financial position underpin growth.
Denali Therapeutics price target raised to $36 from $32 at BTIG
BTIG raised the firm’s price target on Denali Therapeutics (DNLI) to $36 from $32 and keeps a Buy rating on the shares. The company has established a clear path to…
Denali Therapeutics price target lowered to $34 from $37 at Stifel
Stifel analyst Paul Matteis lowered the firm’s price target on Denali Therapeutics (DNLI) to $34 from $37 and keeps a Buy rating on the shares.
Denali Therapeutics reports Q4 EPS (73c), consensus (75c)
“In 2025, we made meaningful progress toward delivering urgently needed treatment options for people living with neurodegenerative diseases and lysosomal storage disorders, building on the strong scie...
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the fourth quarter and full year ended December 31, 2025, an...
Denali Therapeutics initiated with a Peer Perform at Wolfe Research
Wolfe Research analyst Rudy Li initiated coverage of Denali Therapeutics (DNLI) with a Peer Perform rating and no price target The firm launched coverage of the neuroscience biotech sector with…